Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 9/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 5/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051471 | 0.91 | F2R (0.46) | F2RCNR1TMEM97MGLLGRM5 | |
| SCHEMBL1054662 | 0.91 | F2R (0.45) | F2RCNR1TMEM97GRM5USP30 | |
| SCHEMBL1056869 | 0.90 | F2R (0.43) | F2RCNR1TMEM97MGLLGRM5 | |
| SCHEMBL1054524 | 0.90 | F2R (0.56) | F2RCNR1TMEM97MGLLGRM5 | |
| SCHEMBL1054526 | 0.90 | F2R (0.49) | F2RCNR1TMEM97MGLLGRM5 | |
| SCHEMBL1056032 | 0.89 | F2R (0.43) | F2RCNR1TMEM97MGLLGRM5 | |
| SCHEMBL3763534 | 0.89 | F2R (0.46) | F2RCNR1TMEM97MGLLGRM5 | |
| SCHEMBL1056447 | 0.89 | F2R (0.57) | F2RCNR1TMEM97USP30 | |
| SCHEMBL1052991 | 0.88 | F2R (0.39) | F2RCNR1TMEM97MGLLUSP30 | |
| SCHEMBL3761092 | 0.83 | F2R (0.43) | F2RCNR1TMEM97MGLLGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PIGO | F2R 1339/4885CNR1 460/4885TMEM97 903/4885 |
| US-20120220563-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885CNR1 460/4885TMEM97 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.